Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy

Liver International

Volumn 31, Issue 3, 2011, Pages 330-339

  MéNdez Navarro, Jorge ^a,b   Corey, Kathleen E ^a   Zheng, Hui ^c   Barlow, Lydia L ^a   Jang, Jae Young ^a,d   Lin, Wenyu ^a   Zhao, Hong ^a   Shao, Run Xuan ^a   McAfee, Steven L ^a   Chung, Raymond T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HOSPITAL DE ESPECIALIDADES   (Mexico)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Soonchunhyang University   (South Korea)

Author keywords

Chemotherapy; HBV prophylaxis; HBV re activation; Hepatitis B; Non Hodgkin lymphoma; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PREDNISONE; RITUXIMAB; TENOFOVIR; VINCRISTINE;

ADULT; AGED; ANTIBODY ISOLATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DEATH; DRUG DOSE INCREASE; FEMALE; HEPATITIS B; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; RETROSPECTIVE STUDY; SCREENING; SEROLOGY; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; FEMALE; HEPATITIS ANTIBODIES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MASS SCREENING; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; SEROLOGIC TESTS; VIRUS ACTIVATION;

EID: 79551513633     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02332.x     Document Type: Article

References (28)

1. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-1500.
2. Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009; 29 (Suppl. 1): 100-7.
3. Vierling JM. The immunology of hepatitis B. Clin Liver Dis 2007; 11: 727-59.
4. Sorrell MF, Belongia EA, Costa J, et al. National institutes of health consensus development conference statement: management of hepatitis B. Ann Intern Med 2009; 150: 104-10.
5. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009 AASLD practice guidelines. Hepatology 2009; 50: 1-36.
6. Hoofnagle JH Reactivation of hepatitis B. Hepatology 2009; 49: S156-65.
7. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-83.
8. Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 2008; 15: 89-102.
9. Kohrt HE, Ouyang DL, Keeffe EB. Antiviral prophylaxis for chemotherapy-Induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis 2007; 11: 965-91.
10. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519-28.
11. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-9.
12. Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in Non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008; 47: 844-53.
13. de Franchis R, Hadengue A, Lan G, et al. EASL international consensus conference on hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement. J Hepatol 2003; 39: S3-25.
14. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations AASLD practice guidelines. Hepatology 2004; 39: 857-61.
15. EASL Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
16. Lovric S, Erdbruegger U, Kumpers P, et al. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients. Nephrol Dial Transplant 2009; 24: 179-85.
17. Lim SH, Beers SA, French RR, et al. Anti-CD20 monoclonal antibodies-historical and future perspectives. Haematologica 2010; 95: 135-43.
18. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42.
19. Li JM, Wang L, Shen Y, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients. Ann Hematol 2007; 86: 639-45.
20. Li Y-H, He Y-F, Jiang W-Q, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006; 106: 1320-5.
21. Pei S-N, Chen C-H, Lee C-M, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010; 89: 255-62.
22. Simpson N, Simpson P, Ahmed A, et al. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with lamivudine. J Clin Gastroenterol 2003; 37: 68-71.
23. Dillon R, Hirschfield GM, Allison ME, Rege KP. Fatal reactivation of hepatitis B after chemotherapy for lymphoma. BMJ 2008; 337: 756-8.
24. Law JK, Ho JK, Hoskins PJ, et al. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005; 46: 1085-9.
25. Sanchez MJ, Buti M, Homs M, et al. Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. J Hepatol 2009; 51: 1091-6.
26. Yeo W, Chan TC, Leung N, et al. Hepatitis B virus reactivation in Lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-11.
27. Yeo W, Johnson P. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-20.
28. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006; 354: 1011-20.